Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 1.00 |
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898960 | 0.90 | MMP13 (1.00) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL8361683 | 0.87 | MMP13 (0.76) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL7074343 | 0.86 | MMP2 (0.76) | MMP13MMP2FPR2PROKR1ACLY | |
| SCHEMBL8363030 | 0.85 | MMP13 (0.82) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL8364661 | 0.84 | MMP13 (0.73) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL5898931 | 0.84 | MMP2 (0.76) | MMP13MMP2EPHX2ACLYSMN1; SMN2 | |
| SCHEMBL5898984 | 0.84 | MMP13 (1.00) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL8365029 | 0.83 | MMP13 (0.70) | MMP13MMP2FPR2PROKR1LIPE | |
| SCHEMBL8361679 | 0.78 | MMP13 (0.64) | MMP13MMP2FPR2PROKR1EPHX2 | |
| SCHEMBL7764828 | 0.77 | MMP13 (0.78) | MMP13MMP2FPR2PROKR1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | disclosed |
| US-6794511-B2 | AN ENZYME INHIBITORS OF METALLOPROTEASE; TREATING CONNECTIVE TISSUE DEGRADATION CAUSED BY INFLAMMATION OR TUMOR | G. D. SEARLE | 2004-09-21 | — | — | US | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030191317-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO., (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1177173-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001085680-A2 | SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000069819-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191317-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP13 5/4885MMP2 2/4885FPR2 2059/4885 |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP13 5/4885MMP2 2/4885FPR2 2059/4885 |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | MMP13 8/4885MMP2 7/4885FPR2 2166/4885 |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | MMP13 26/4885MMP2 27/4885FPR2 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.